Brexit-related guidance for companies

The European Medicines Agency (EMA) and the European Commission are providing guidance to help pharmaceutical companies responsible for both human and veterinary medicines prepare for the United Kingdom's (UK) withdrawal from the European Union (EU), a process known as 'Brexit'.

This aims to ensure that companies are ready to take the necessary steps to enable undisrupted supply of their medicines in the EU for the benefit of patients, based on the assumption that the UK will become a third country.

Extension of the period under 'Article 50'

On 29 October 2019, the European Council agreed to a further extension of the date for the UK’s withdrawal from the EU. The extension will last as long as necessary and, in any event, no longer than 31 January 2020. For more information, see:

The UK remains an EU Member State for the duration of the extension.

EMA calls on all pharmaceutical companies in the EU to continue their preparedness for the UK’s withdrawal.

Based on the European Council decision, and until further notice, the deadline of 29 March 2019 referred to in Brexit related guidance should be understood as referring to 31 January 2020.

Guidance on centrally authorised products

Companies should check this page regularly for guidance on the consequences of Brexit, as EMA and the European Commission are delivering and maintaining a series of guidance documents.

DocumentContains information onLast updated
February 2019
  • necessary changes to marketing authorisations
  • impact on ongoing procedures
  • impact on generic, hybrid and biosimilar applications
  • necessary changes to orphan designations
  • submission of safety information originating in the UK
  • applying for exemptions for batch testing of medicines in the UK after 29 March 2019 
March 2019
  • legal obligations
February 2019
  • batch testing of medicines in the UK after 29 March 2019
February 2019


Brexit-preparedness of centrally authorised products

According to EU law, the marketing authorisation holder, QPPV, pharmacovigilance system master file (PSMF) and certain manufacturing sites need to be based in the European Economic Area (EEA) for a company to be able to market a medicine in the EU. 

EMA continues to urge pharmaceutical companies to make the changes required by EU law to enable them to continue to market a medicine in the EU after Brexit.

In June 2019, just three marketing authorisations (for human medicines) still needed to be transferred from the UK to an EU27 Member State. Good progress had also been made for products with QPPVs and pharmacovigilance system master files (PSMFs) based in the UK. Although companies have reassured EMA that their plans are in place, the Agency reminds them of their responsibility to make the necessary changes required by EU law as soon as possible.

EMA carried out a Brexit-preparedness survey in 2018, to gather information from marketing authorisation holders on their preparedness for Brexit.

The main aim was to to obtain information on the timelines for submission of necessary regulatory changes, and identify any centrally authorised products at potential risk of supply shortages. EMA published a high-level summary of the results in July 2018:

Based on the survey results, EMA was concerned about potential supply shortages for 108 medicines (88 human and 20 veterinary). EMA contacted the marketing authorisation holders between July and September 2018 and received reassurance on the regulatory planning for a significant proportion. In October 2018, EMA revised the number down to 31 centrally authorised products (19 human medicines and 12 veterinary medicines) for which it remained concerned about potential Brexit-related supply disruptions. 

EMA, together with its scientific committees, assessed how critical these products are for the treatment of the disease they target. National competent authorities will check whether there are possible therapeutic alternatives available in their country. 

The survey involved marketing authorisation holders for 694 centrally authorised products (661 human and 33 veterinary products) either located in the UK or with quality control, batch release and/or import or manufacturing sites, or a QPPV or PSMF in the UK.

Exemption for batch testing of medicines in UK

Marketing authorisation holders who are unable to transfer their batch testing site from the UK to the EU27/EEA by the date of Brexit may be permitted, for a limited period of time, to continue relying on quality control testing performed in the UK after Brexit.

A key condition for this exemption is that all necessary steps have been taken to prepare the transfer of the quality control testing site to the EU27/EEA.

Marketing authorisation holders requesting the exemption must confirm and set out their precise timetable for transfering the quality control testing site. The transfer shoud be completed quickly and in principle by the end of 2019 at the latest. 

It is essential that marketing authorisation holders use the time remaining to complete their preparations, so that by 1 January 2020 all batch testing facilities are fully transferred to the EU27/EEA and the necessary regulatory submissions are completed. 

For more information, see:

For requesting an exemption for a centrally authorised medicine, marketing authorisation holders should use the following template:

FileTemplate for requesting a time-limited exemption to continue batch control testing in the UK

They should submit a scanned and signed copy as well as an editable version of the request to EMA via email or Eudralink to (copying the Product Lead and the product mailbox for human medicines and for veterinary medicines) as soon as possible and no later than by the date of Brexit.

EMA will notify individual marketing authorisation holders whether their request has been granted as quickly as possible. Marketing authorisation holders whose request for exemption has been granted must notify the relevant national competent authority(ies). For more information, see page 22 of  PDF iconEMA's practical guidance

Submission of Brexit-related type I variations

EMA encourages marketing authorisation holders to submit Brexit-related type IA and type IB variations as early as possible, to enable EMA to confirm compliance with regulatory and legal requirements by the date of Brexit. 

When submitting these variations via the eSubmission Gateway, applicants should make sure they tick the 'Brexit-related procedure' checkbox. For more information and guidance, see:

Marketing authorisation holders should email (copying the Product Lead and the product mailbox) if their plans change for submitting Brexit-related post-authorisation applications. 

For procedural or regulatory queries related to type I variations for human medicines, contact or

Change of format for pre-submission meetings

For human and veterinary initial marketing authorisation applications, EMA holds all pre-submission meetings requested as of 1 October 2018 remotely, either via teleconference or virtual meeting. This is expected to last until the Agency is fully operational in its new permanent premises. For more information, see:

EMA holds pre-submission meetings for scientific advice exclusively by teleconference as of September 2018.

How useful was this page?

Add your rating
9 ratings
1 rating
3 ratings
3 ratings
9 ratings